Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback